Securities code: 300584 securities abbreviation: Nanjing Hicin Pharmaceutical Co.Ltd(300584) Announcement No.: 2022-008 Nanjing Hicin Pharmaceutical Co.Ltd(300584)
Announcement on the acquisition of project filing by holding subsidiaries
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Anqing Huichen Pharmaceutical Co., Ltd. (hereinafter referred to as "Anqing Huichen"), a holding subsidiary of Nanjing Hicin Pharmaceutical Co.Ltd(300584) (hereinafter referred to as "the company"), obtained the project record issued by the Economic Development Bureau of Anqing high tech Industrial Development Zone on February 18, 2022. The details are as follows:
1、 Basic information of project filing
Project Name: construction project of Anqing Huichen Pharmaceutical Co., Ltd. with an annual output of 100 tons of anti covid-19 drug nimatovir API and its key intermediates
Project legal person: Anqing Huichen Pharmaceutical Co., Ltd
Project code: 2202-340877-04-05-848790
Project construction address: No. 99, Dingxiang Road, Anqing high tech Industrial Development Zone, Anqing City, Anhui Province
Construction nature: new construction
Industry / national standard industry: pharmaceutical / chemical API manufacturing
Construction scale and content: a set of production unit with an annual output of 50 tons of nimatovir ((1R, 2S, 5S) - N - ((1s) - 1-cyano-2 - ((3S) - 2-oxopyrrolidine-3-yl) ethyl) - 3 - ((2S) - 3,3-dimethyl-2 - (2,2-trifluoroacetamide) butyryl) - 6,6-dimethyl-3-azabicyclo (3.1.0) hexane-2-formamide) products, A set of production unit for intermediate (cp-w1001: (1R, 2S, 5S) - 6,6-dimethyl-3-azabicyclo (3.1.0) hexyl-2-carboxylic acid methyl ester hydrochloride) with an annual output of 50 tons.
New production capacity: Product: namatovir 50t / A, intermediate (cp-w1001) 50t / A.
Project commencement time: 2022
Project completion time: 2022
The total investment of the project is 50.08 million yuan, and the source of funds is self raised by the enterprise.
2、 Internal review procedures and impact on the company
According to the Shenzhen Stock Exchange GEM Listing Rules, the articles of association and other relevant provisions, the investment project is within the decision-making authority of the general manager of the company and does not need to be submitted to the board of directors and the general meeting of shareholders for deliberation.
The capital source of this project construction is all self raised funds, which will not have an adverse impact on the company's financial and operating conditions, and is in line with the interests of the company and all shareholders. The project relies on the company's talent advantages and technical reserves in synthetic chemistry. After the completion of the project, it will help to improve the company's production capacity of antiviral APIs and intermediates, enhance the company's competitive advantage and comprehensive competitiveness, and comply with the company's development plan.
3、 Risk tips
1. Before the commencement of the project, the relevant procedures of planning, environmental protection, safety production and energy evaluation need to be handled according to law, which has the risk of not being approved by relevant government departments, but taking a long time. Please pay attention to investment risks.
2. The project is currently in the research and preparation stage, and there is a risk of uncertainty in the time of equipment installation, commissioning, trial production and other links. Please pay attention to investment risks.
3. The project is currently in the research preparation stage. Affected by external factors such as epidemic situation change, market demand change, market competition, technology change, macro policy and industry policy, and internal factors such as the company's internal management, process technology and construction funds, the project investment plan may be terminated, partially terminated, the investment plan may be changed and the income may not meet the expected risk. Please pay attention to investment risks.
4. The API of the project cannot be sold because it involves patents. At present, it is only used for scientific research of the company. There is serious uncertainty about whether the project can achieve the company's scientific research objectives in the future. Please pay attention to investment risks.
5. The intermediates involved in this project are only sold in the non regulatory market. At present, there is no fixed order, and the company has no commercial cooperation with Pfizer. The channel of 6,6-dimethyl-3-azabicyclo (3.1.0) hexane (CAS No.: 943516-54-9), the raw material required for the synthesis of the intermediate, is still unstable, the price fluctuates, and the income after the project is put into operation in the future is uncertain.
6. Recently, the company's share price in the secondary market fluctuated greatly, and the dynamic P / E ratio was significantly higher than the average level of the same industry, but there was no significant change in the internal and external business environment. Please pay attention to investment risks. 7. The company's 2021 annual performance forecast was disclosed on January 19, 2022. In 2021, the net profit attributable to the shareholders of the listed company is expected to be 288352700 yuan – 298961200 yuan, an increase of 422.09% - 441.30% over the same period of the previous year; Net profit attributable to shareholders of listed companies after deducting non recurring profits and losses
26.5213 million yuan – 37.1298 million yuan, a decrease of 30% - 50% over the same period last year. Please pay attention to investment risks.
4、 Documents for future reference
1. Project filing form
It is hereby announced.
Nanjing Hicin Pharmaceutical Co.Ltd(300584) board of directors February 20, 2022
